This is a working overview of Selank, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-19. Anything still debated is marked as such rather than presented as settled.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Amitabha Chattopadhyay is an Indian scientist working in the areas of membrane and receptor biology and biophysics . He is presently a CSIR Bhatnagar Fellow at the Center for Cellular and Molecular Biology and served as the founding dean of biological sciences at the Academy of Scientific and Innovative Research (AcSIR). In addition, he is a distinguished visiting professor at the Indian Institute of Technology Bombay, adjunct professor at the Jawaharlal Nehru University (New Delhi), Tata Institute of Fundamental Research, Indian Institute of Science Education and Research (Kolkata), Swinburne University of Technology (Australia), and honorary professor at the Jawaharlal Nehru Centre for Advanced Scientific Research (Bangalore). He was elected a Fellow of the Royal Society of Chemistry in 2013 and Royal Society of Biology in 2017. Chattopadhyay has authored more than 300 research papers and has an h-index of 65. In 2016, Chattopadhyay won The World Academy of Sciences in Biology for his seminal contribution in understanding the role of membrane cholesterol in the organization and function in healthy and diseased conditions.
When genotypes grown together in a diverse population have different profiles of resource use they complement each other in the exploitation of the limiting resource and therefore are subject to smaller between-plant competition. In case of disease or environmental change some plants will take over when others fail. Yield stability over years and environments can be better than pure lines due to compensation. Participatory plant breeding (PPB) methods represent alternatives aimed to improve local adaptation breeding, to promote genetic diversity, to empower farmers and rural communities. In PPB farmers are actively participating in developing new cultivars or populations, e.g. by performing selection.
Diagnosis of gonococcal and other neisserian infections: amplification of specific N. gonorrhoeae DNA or RNA sequences for detection. Diagnosis of urogenital C. trachomatis infections Detection of Mycobacterium tuberculosis Detection of HIV RNA or DNA Detection of zoonotic coronaviruses Diagnostic test for SARS-CoV-2 Detection of antibiotic resistant bacteria following antibiotic treatment
Sources: en.wikipedia.org
In Egypt, the Israelites grew from a family into a nation and were enslaved before being liberated by Moses, whose successor Joshua oversaw the Israelite conquest of Canaan. After taking control of Canaan, they established a kritarchy (rule of what the Bible calls judges, or shophetim) and eventually founded the United Monarchy, which eventually split into Israel in the north and Judah in the south. Scholars generally consider the Hebrew Bible's narrative to be part of the Israelites' national myth, but believe that there is a "historical core" to some of the events in it. The historicity of the United Monarchy is widely disputed. In the context of Hebrew scripture, Canaan is also variously described as the Promised Land, the Land of Israel, Zion, or the Holy Land. Jews and Samaritans are two closely related ethno-religious groups descended from the Israelites. Jews trace their ancestry to the tribes that inhabited the Kingdom of Judah, namely Judah, Benjamin, and partially Levi, while Samaritans trace their ancestry to the tribes that inhabited the Kingdom of Israel and remained after the Assyrian captivity, namely Ephraim, Manasseh, and partially Levi. Furthermore, Judaism and Samaritanism are fundamentally rooted in Israelite religious and cultural traditions. There are several other groups claiming affiliation with the Israelites, but most of them have unproven lineage and are not recognized as either Jewish or Samaritan.
Abu Abdurrahman Shishani Abdul-Malik Shishani Abdul-Hakim Shishani Hamza Shishani Abu Al-Bara al-Kavkazi Muslim Shishani Abu Turab Shishani Umar Shishani Tarkhan Gaziev Sayfullakh Shishani Salahuddin Shishani Hayrullah Shishani Sayful-Islam Shishani Naib Shishani Mohannad Shishani Muhammad Shishani Al Bara Shishani Abu Bakr Shishani Halid Shishani Ali Shishani Abu Musa al Shishani ISIS supporters
Steven Eugene Wilson (born 1951) is an American ophthalmologist and professor at Cleveland Clinic, where he is a surgeon and directs corneal research. He has also received honors for several published historical fiction novels. His research has focused on corneal cellular responses to injury and surgery, with his most-cited work being about keratocyte apoptosis, as well as cellular and molecular interactions involved in homeostasis, wound healing, and diseases of the cornea. He holds two United States patents related to corneal healing. He previously served as a professor and chair of the Department of Ophthalmology at the University of Washington in Seattle from 1998 to 2003, and was named Grace E. Hill Endowed Chair in Vision Research.
Consumers yield isotopic signatures that reflect the sulfur reservoir(s) of the dietary protein source. Animal proteins sourced from marine ecosystems tend to have δ34S values between +16 and +17‰, terrestrial plants range from -7‰ to +8‰, while proteins from freshwater and terrestrial ecosystems are highly variable. The sulfate content of the modern ocean is well-mixed with a δ34S of approximately +21‰, while riverine water is heavily influenced by sulfur-bearing minerals in surrounding bedrock and terrestrial plants are influenced by the sulfur content of local soils. Estuarian ecosystems have increased complexity due to seawater and river inputs. The extreme range of δ34S values for freshwater ecosystems often interferes with terrestrial signals, making it difficult to use the sulfur system as the sole tool in paleodiet studies. Various studies have analyzed the isotopic ratios of sulfur in mummified hair. Hair is a good candidate for sulfur studies as it typically contains at least 5% elemental sulfur. One study incorporated sulfur isotope ratios into their paleodietary investigation of four mummified child victims of Incan sacrificial practices. δ34S values helped them conclude that the children had not been eating marine protein before their death. Historical insight coupled with consistent sulfur signatures for three of the children suggests that they were living in the same location 6 months prior to the sacrifice.
Sources: en.wikipedia.org
Founded in 1984, Bio-Synthesis, Inc. was known as OCS Laboratories and was one of the first companies providing commercially available synthetic oligonucleotides to the biomedical research community worldwide. It was the first producer of commercially available synthetic DNA and became a producer of synthetic peptides in 1985, and became the only company to provide both synthetic DNA and peptide under one roof. Also in 1985 the process, now known as PCR, was discovered by Mullis et al. A key activity for Bio-Synthesis was to synthesize large number of PCR primer thus assisting and solidifying the early adoption of this now common and crucial process in biology.
T-box, brain, 1 is a transcription factor protein important in vertebrate embryo development. It is encoded by the TBR1 gene. This gene is also known by several other names: T-Brain 1, TBR-1, TES-56, and MGC141978. TBR1 is a member of the TBR1 subfamily of T-box family transcription factors, which share a common DNA-binding domain. Other members of the TBR1 subfamily include EOMES and TBX21. TBR1 is involved in the differentiation and migration of neurons and is required for normal brain development. TBR1 interacts with various genes and proteins in order to regulate cortical development, specifically within layer VI of the developing six-layered human cortex. Studies show that TBR1 may play a role in major neurological diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and autism spectrum disorder (ASD).
Clinical data management Clinical Quality Management System Clinical trial management system Clinical trial Electronic data capture Electronic Common Technical Document (eCTD) Drug development Stuart Summerhayes, CDM Regulations Procedures Manual, Blackwell Publishing, ISBN 1-4051-0740-5 Tai BC, Seldrup J., A review of software for data management, design and analysis of clinical trials, Ann Acad Med Singap. 2000 Sep;29(5):576-81. Greenes RA, Pappalardo AN, Marble CW, Barnett GO., Design and implementation of a clinical data management system, Comput Biomed Res. 1969 Oct;2(5):469-85. CDMS at Mayo Clinic Association for Clinical Data Management Society for Clinical Data Management French network of Data Managers in Academic biomedical research Data Quality Research Institute Data Security Software for Clinics
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.